LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Date	Price Target	Rating	Analyst
4/10/2025	$143.00	Buy	Stifel
10/3/2024	$135.00	Outperform	Oppenheimer
7/30/2024	$130.00	Outperform	RBC Capital Mkts
2/22/2022	$180.00 → $130.00	Buy	Benchmark
2/18/2022	$185.00 → $165.00	Overweight	Barclays
9/22/2021	$174.00 → $180.00	Overweight	Barclays
7/30/2021	$200.00 → $190.00	Buy	Roth Capital

Ligand Pharmaceuticals Incorporated

Peers

Recent Analyst Ratings for Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CLO & Secretary Reardon Andrew sold $57,271 worth of shares (500 units at $114.54), decreasing direct ownership by 2% to 32,403 units (SEC Form 4)

Director Gray Nancy Ryan was granted 1,209 shares, increasing direct ownership by 18% to 8,094 units (SEC Form 4)

Director Aryeh Jason was granted 1,209 shares, increasing direct ownership by 2% to 79,289 units (SEC Form 4)

Director Lamattina John L was granted 1,209 shares, increasing direct ownership by 4% to 30,724 units (SEC Form 4)

Director Zimmermann Martine was granted 1,209 shares and covered exercise/tax liability with 188 shares, increasing direct ownership by 29% to 4,558 units (SEC Form 4)

Director Sabba Stephen L was granted 1,209 shares, increasing direct ownership by 4% to 33,793 units (SEC Form 4)

Director Kozarich John W was granted 1,209 shares, increasing direct ownership by 3% to 47,390 units (SEC Form 4)

Director Haas Jason was granted 1,209 shares, increasing direct ownership by 22% to 6,606 units (SEC Form 4)

CLO & Secretary Reardon Andrew covered exercise/tax liability with 897 shares and sold $104,000 worth of shares (1,000 units at $104.00), increasing direct ownership by 46% to 32,903 units (SEC Form 4)

Director Kozarich John W exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 5% to 46,181 units (SEC Form 4)

Ligand Pharmaceuticals Incorporated Press Releases

Fastest customizable press release news feed in the world

Ligand Announces 2025 Investor Day in New York City

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand Reports First Quarter 2025 Financial Results

Ligand to Participate in May Investor Conferences

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Ligand to Participate in March Investor Conferences

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Ligand Pharmaceuticals Incorporated Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stifel initiated coverage on Ligand Pharma with a new price target

Oppenheimer initiated coverage on Ligand Pharma with a new price target

RBC Capital Mkts initiated coverage on Ligand Pharma with a new price target

Benchmark reiterated coverage on Ligand Pharmaceuticals with a new price target

Barclays reiterated coverage on Ligand Pharmaceuticals with a new price target

Barclays reiterated coverage on Ligand Pharmaceuticals with a new price target

Roth Capital reiterated coverage on Ligand Pharmaceuticals with a new price target

Barclays reiterated coverage on Ligand Pharmaceuticals with a new price target

Stephens resumed coverage on Ligand Pharma with a new price target

Craig Hallum reiterated coverage on Ligand Pharmaceuticals with a new price target

Ligand Pharmaceuticals Incorporated Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

SEC Form 4: Davis Todd C bought $237,529 worth of shares (4,000 units at $59.38), increasing direct ownership by 6% to 73,090 units

Ligand Pharmaceuticals Incorporated SEC Filings

Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Ligand Pharmaceuticals Incorporated

SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated

SEC Form DEF 14A filed by Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits